The FDA approved Tecentriq with chemotherapy for Stage III dMMR colon cancer - the first immunotherapy regimen here, halving the risk of recurrence or death.
October 18, 2026
Wealth, Power & Influence
The FDA approved Tecentriq with chemotherapy for Stage III dMMR colon cancer - the first immunotherapy regimen here, halving the risk of recurrence or death.